DE2953223C2 - - Google Patents

Info

Publication number
DE2953223C2
DE2953223C2 DE2953223T DE2953223T DE2953223C2 DE 2953223 C2 DE2953223 C2 DE 2953223C2 DE 2953223 T DE2953223 T DE 2953223T DE 2953223 T DE2953223 T DE 2953223T DE 2953223 C2 DE2953223 C2 DE 2953223C2
Authority
DE
Germany
Prior art keywords
glucuronic acid
glucuronide
acid
aglycone
acetyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2953223T
Other languages
German (de)
English (en)
Other versions
DE2953223T1 (de
Inventor
David Rubin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Century Science Corp (ndgesdstaates Delaware)
Original Assignee
Schwartz I S
Schwimmer A W
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US05/951,270 external-priority patent/US4424348A/en
Priority claimed from US05/951,269 external-priority patent/US4584368A/en
Priority claimed from US06/011,619 external-priority patent/US4327074A/en
Application filed by Schwartz I S, Schwimmer A W filed Critical Schwartz I S
Publication of DE2953223T1 publication Critical patent/DE2953223T1/de
Application granted granted Critical
Publication of DE2953223C2 publication Critical patent/DE2953223C2/de
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2334/00—O-linked chromogens for determinations of hydrolase enzymes, e.g. glycosidases, phosphatases, esterases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Optics & Photonics (AREA)
  • General Physics & Mathematics (AREA)
  • Physiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE792953223T 1978-10-13 1979-10-02 B-glucuronidase activity and/or ph-dependent pharmaceuticals and their methods of production and use for selective treatment of diseases Granted DE2953223T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US05/951,270 US4424348A (en) 1978-10-13 1978-10-13 Methods of manufacture of nitrile-containing glucuronic acid conjugates
US05/951,269 US4584368A (en) 1978-10-13 1978-10-13 β-Glucuronidase activity and/or pH-dependent pharmaceuticals and thier methods of production
US06/011,619 US4327074A (en) 1978-10-13 1979-02-12 Method for diagnosis and selective treatment of infections of bacteria having β-glucuronidase activity
PCT/US1979/000809 WO1980000791A1 (en) 1978-10-13 1979-10-02 B-glucuronidase activity and/or ph-dependent pharmaceuticals and their methods of production and use for selective treatment of diseases

Publications (2)

Publication Number Publication Date
DE2953223T1 DE2953223T1 (de) 1980-11-27
DE2953223C2 true DE2953223C2 (enrdf_load_stackoverflow) 1989-05-18

Family

ID=27359461

Family Applications (1)

Application Number Title Priority Date Filing Date
DE792953223T Granted DE2953223T1 (de) 1978-10-13 1979-10-02 B-glucuronidase activity and/or ph-dependent pharmaceuticals and their methods of production and use for selective treatment of diseases

Country Status (12)

Country Link
JP (1) JPS55500837A (enrdf_load_stackoverflow)
AU (1) AU534068B2 (enrdf_load_stackoverflow)
CA (1) CA1148086A (enrdf_load_stackoverflow)
CH (1) CH652724A5 (enrdf_load_stackoverflow)
DE (1) DE2953223T1 (enrdf_load_stackoverflow)
FR (2) FR2440374B1 (enrdf_load_stackoverflow)
GB (1) GB2055044B (enrdf_load_stackoverflow)
IL (1) IL58352A (enrdf_load_stackoverflow)
IT (1) IT1164730B (enrdf_load_stackoverflow)
NL (1) NL7920107A (enrdf_load_stackoverflow)
SE (1) SE461983B (enrdf_load_stackoverflow)
WO (1) WO1980000791A1 (enrdf_load_stackoverflow)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4490523A (en) * 1981-11-10 1984-12-25 Ely J. Rubin Mandelonitrile triacetyl glucuronate and process for preparing same
AU594855B2 (en) * 1988-01-15 1990-03-15 Baker Norton Pharmaceuticals, Inc. Glucuronic acid derivatives of opioid antagonists
DE59610819D1 (de) * 1995-03-30 2003-12-18 Werner Kreutz Arzneistoffe zur selektiven bekämpfung von tumorgewebe
WO2014138722A1 (en) * 2013-03-08 2014-09-12 Cognate3 Llc Process for the preparation of a non-corrosive base solution and methods of using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB788855A (en) * 1953-06-30 1958-01-08 Ernst Theodore Krebs Improvements in or relating to mandelo-nitrile-glucuronosides and method of making the same
US2985664A (en) * 1957-05-29 1961-05-23 Ernst T Krebs Hexuronic acid derivatives
US3758455A (en) * 1970-05-14 1973-09-11 Chugai Pharmaceutical Co Ltd Reof mycophenolic acid glucuronide and the process for the preparation the
DE2212014A1 (de) * 1971-04-21 1972-10-26 Deutsche Akademie der Wissenschaf ten zu Berlin, χ 1199 Berlin Verfahren zur fermentativen Spaltung von Transportformen von Chemotherapeutika, insbesondere Cancerostatica
USRE29465E (en) * 1972-08-14 1977-11-01 Eli Lilly And Company Psoriasis treatment with mycophenolic acid
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
US3959253A (en) * 1973-07-02 1976-05-25 Merck & Co., Inc. β-D-glucosyluronic acid derivatives
JPS5325534A (en) * 1976-08-24 1978-03-09 Rikagaku Kenkyusho Mandelic acid glucosides and their anti-cancerous preparations

Also Published As

Publication number Publication date
IT1164730B (it) 1987-04-15
CH652724A5 (de) 1985-11-29
FR2449284A1 (fr) 1980-09-12
AU534068B2 (en) 1984-01-05
SE8004369L (sv) 1980-06-12
CA1148086A (en) 1983-06-14
AU5112079A (en) 1981-04-16
JPS55500837A (enrdf_load_stackoverflow) 1980-10-23
FR2440374A1 (fr) 1980-05-30
GB2055044A (en) 1981-02-25
DE2953223T1 (de) 1980-11-27
WO1980000791A1 (en) 1980-05-01
FR2440374B1 (fr) 1986-03-21
NL7920107A (nl) 1980-08-29
IL58352A (en) 1985-11-29
GB2055044B (en) 1983-04-20
IT7950529A0 (it) 1979-10-11
SE461983B (sv) 1990-04-23

Similar Documents

Publication Publication Date Title
EP1299406B1 (de) Curcumin-derivate mit gegenüber curcumin verbesserter wasserlöslichkeit und diese enthaltende arzneimittel
DE69928410T2 (de) Selenium enthaltende zusammensetzung zur behandlung von systemischen entzündungssyndromen
EP0841949B1 (de) Verwendung von saccharid-konjugaten
DE3609052C2 (de) Anthracyclinglykoside, Verfahren zu ihrer Herstellung und sie enthaltende Zubereitungen
DE2701405C2 (de) Triferridoxorubicin, Verfahren zu dessen Herstellung und diese Verbindung enthaltendes pharmazeutisches Mittel
DE102011112496A1 (de) 4-Methylcatecholderivate und deren Verwendung
DE60119317T2 (de) Krebsbehandlungsmittel für epithelzellen
DE3115080C2 (de) Arzneimittel enthaltend Cytidindiphosphocholin und Lecithin
DE2953223C2 (enrdf_load_stackoverflow)
DE2924692C2 (enrdf_load_stackoverflow)
EP0817623B1 (de) Arzneistoffe zur selektiven bekämpfung von tumorgewebe
EP0655249A1 (de) Moenomycin als Arzneimittel zur Behandlung von Magengeschwüren
DE3031788C2 (enrdf_load_stackoverflow)
DE2428409C3 (de) S3'-Bis-(3-hydroxy-4-hydroxymethyl-2-methyl-5-pyridylmethyl)-carbonodithioat, dessen pharmakologisch verträgliche Salze und Arzneimittel
DE4201942A1 (de) Phenonverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
DE3515178A1 (de) Verfahren zur herstellung von neuen anthracyclinkonjugaten anionischer polymerer
DE3877499T2 (de) 2,6-diamino-3-phenyl-azo-pyridin enthaltendes tier- und humanarzneimittel mit antiviraler und antitumoraler aktivitaet.
DE3301489C2 (enrdf_load_stackoverflow)
DE3122689C2 (de) N-Trifluoracetyl-adriamycin-14-0-hemiglutarat und -hemiadipat und diese Verbindungen enthaltende pharmazeutische Zubereitungen
EP0152860B1 (de) Verwendung von Cephemverbindungen zur Herstellung eines Arzneimittels für die Modulation des Immunsystems
DE1543150C (de) Tetracyclin-guajakol-4-su\fonat und Verfahren zu dessen Herstellung
EP0432309B1 (de) Neue Zuckerderivate, Verfahren zu ihrer Herstellung und ihre Verwendung
EP0443198B1 (de) Diterpene mit immunmodulatorischer Wirkung
DE2265235A1 (de) Heilmittel
CH688398A5 (de) Verwendung von 2-Beta-D-Ribofuranosylthiazol-4-carboxamid und verwandter Verbindungen fuer die Erzeugung von Medikamenten mit Antitumor-Aktivitaet.

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
D2 Grant after examination
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CENTURY SCIENCE CORP. (N.D.GES.D.STAATES DELAWARE)

8328 Change in the person/name/address of the agent

Free format text: DEUFEL, P., DIPL.-WIRTSCH.-ING.DR.RER.NAT. HERTEL, W., DIPL.-PHYS. LEWALD, D., DIPL.-ING., PAT.-ANWAELTE, 8000 MUENCHEN

8339 Ceased/non-payment of the annual fee